Vera Therapeutics aligns with FDA on accelerated kidney drug readout

Vera Therapeutics (NASDAQ:VERA) has reached an agreement with the U.S. Food and Drug Administration to accelerate the regulatory timeline for its experimental kidney disease treatment, clearing the path for an earlier analysis of pivotal Phase 3 data.

The biotechnology company aligned with the regulatory agency on a revised, earlier analysis plan for the estimated glomerular filtration rate (eGFR) from its ongoing ORIGIN Phase 3 trial.

The evaluation is focused on testing the therapeutic candidate, atacicept, in adult patients suffering from IgA nephropathy (IgAN), a rare and serious autoimmune kidney condition.

Under the updated framework, the eGFR clinical results are now anticipated to read out in the third quarter of 2026.

Assuming the forthcoming data points are positive, Vera plans to utilize the findings to submit a supplemental Biologics License Application (sBLA) in the fourth quarter of 2026 to pursue full regulatory approval, which could potentially be granted in 2027.

The revised data strategy unfolds as the company approaches a definitive near-term regulatory decision for the same asset.

The FDA is already reviewing Vera’s initial Biologics License Application (BLA) for the accelerated approval of atacicept in IgAN.

That application has been assigned a targeted action date of July 7, 2026, under the Prescription Drug User Fee Act (PDUFA).